Our expert staff have the competence to creatively address real stake holders value through advanced analytics. Our analytical expertise in providing a complete data package for ” In-Vitro Bioequivalence Establishment ” that serves as a surrogate for the Clinical End Point study need is sought by our partners to waive the need of a clinical study for Bio-equivalence.
• Q1 /Q2 Sameness (Qualitative and Quantitative composition similarity and sameness)
• Q3 Similarity (Micro-structural similarity and sameness) addressing :